Tryptophan Hydroxylase Inhibitors
1 drugsAbout Tryptophan Hydroxylase
Tryptophan Hydroxylase (TPH) is an enzyme essential for synthesizing serotonin, a neurotransmitter regulating diverse physiological processes. By controlling serotonin production, TPH influences mood, sleep, and appetite.
TPH represents a therapeutic target for modulating serotonin levels, though no direct genetic evidence currently links it to specific diseases. Its role in serotonin production makes it relevant to conditions involving serotonin dysregulation.
One FDA-approved drug, XERMELO, targets TPH as a small molecule for one indication. TERSERA is the company marketing XERMELO, approved in 2017.
Top Tryptophan Hydroxylase Drugs
The competitive landscape is highly concentrated, with only one company, TERSERA, having an approved drug.
Low competition suggests an opportunity for new entrants, but also highlights potential market risks.
Tryptophan Hydroxylase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Tryptophan Hydroxylase, using small molecule modality.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing treatments.
Tryptophan Hydroxylase Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Tryptophan Hydroxylase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 | 100% |
| Phase 2 | 9 | 5 | 4 | 0 | 56% |
| Phase 3 | 5 | 3 | 1 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Tryptophan Hydroxylase Drug Approval Timeline (2017 - 2017)
The first and only drug targeting TPH, XERMELO, was approved in 2017.
Recent approval but lack of follow-on drugs indicates either limited potential or untapped opportunity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Tryptophan Hydroxylase. A trial counts if an approved drug acting on Tryptophan Hydroxylase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.